GTBP: קפיטליזציית שוק GT Biopharma Corporation

This chart of GT Biopharma, Inc. (GTBP) asset value demonstrates a market capitalization of 0.01. GT Biopharma, Inc. (GTBP) develops innovative leukemia treatment methods using NK cells for therapy in specialized clinics. Operational activities rely on an international network of laboratories and the air transport of biomaterials. A high barrier to entry is ensured by patents on protein structures and strict FDA control.

GT Biopharma, Inc. (GTBP) aims for leadership in the immunotherapy sector through the development of TriKE NK-cell therapies. Market capitalization digitizes the aggregate value of all shares, reflecting investor confidence in the commercial success of these innovations. This metric captures phases of market euphoria or panic through valuation extremes. The indicator allows for a comparison between the actual scale of the business and analytical forecasts. The market capitalization dynamics of GT Biopharma, Inc. (GTBP) help disciplined investors identify optimal entry points into the asset.